INTERVENTIONS Sessions of GPT and CM were held weekly for the first 12 weeks and monthly thereafter (9 months). Patients received either methylphenidate or placebo for 1 year.
effect of medication on the outcomes of psychological therapy is still largely unknown.
Specific cognitive behavioral programs have been proven more effective than unspecific control conditions (eg, relaxation, supportive therapy, and discussion groups) for adult ADHD. 23, 25, 26 However, the effectiveness of a highly structured group program vs a less specific treatment, eg, clinical management (CM), which simulates practice care in an optimal way, is unknown. Given the recognized need for research, 28 the primary aim of our study was to demonstrate the efficacy of highly structured behavioral GPT compared with less specific treatment (eg, CM) as well as that of methylphenidate compared with placebo after 3 months. Secondary analyses included a comparison of the same effects after 1 year of treatment, the 4 treatment conditions (GPT with methylphenidate; GPT with placebo; CM with methylphenidate; and CM with placebo), measures of depression, and Clinical Global Impression Scale (CGI) score. 29 
Methods

Study Design and Participants
All methodological issues have been described in detail. 21, 30 The Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS) was a factorial, multicenter, randomized clinical trial comparing GPT with CM and methylphenidate with placebo. The full trial protocol appears in Supplement 1. Inclusion and exclusion criteria are listed in eAppendix 1 in Supplement 2. The diagnosis of ADHD, according to DSM-IV and other psychiatric symptoms, was established by psychiatric expert assessment and validated using observer rating scales and self-rating scales, including the Wender Utah Rating Scale (WURS-k; in German), 31, 32 the ADHD diagnostic checklist (ADHD-DC; in German), 33 and the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) (in German). 34, 35 Concurrent use of psychopharmacologic or psychotherapeutic treatments was not allowed outside the trial. The study received ethics committee approval from University of Freiburg. Written informed consent was obtained from all participants.
Randomization and Masking
Eligible patients were randomized in batches of 14 or 15 at a time (1 × 12, 1 × 16). The randomization allowed for GPT in groups of 6 to 9 patients. Either GPT or CM plus a medication number (used to allocate either methylphenidate or placebo) was centrally assigned. 21, 30 Treatments were allocated in a 1:1:1:1 ratio, stratified in blocks of 4 within the center (block size was kept confidential to help ensure concealment; the protocol stated that it was variable). Blocks were sequentially combined for application to patient batches. For patients and therapists, the study was blinded for medication and open for assignment to GPT or CM. Observers rating ADHD symptoms (ADHD-DC, Conners Adult ADHD Rating Scale [CAARS] long German version, [36] [37] [38] [39] and CGI) were blinded to treatment allocation.
Procedures
Following randomization and baseline assessment, participants received methylphenidate hydrochloride (sustained release; initial dosage of 10 mg/d; titration with 10 mg/wk over 6 weeks up to 60 mg/d; individual dosage to a maximum daily dosage of 1.3 mg/kg of body weight) or placebo. Medication adherence was assessed by pill count. The GPT sessions followed a validated manual (eAppendix 2 in Supplement 2). 40, 41 Individual CM was the active, nonpharmacological control condition chosen to simulate general practice. The CM participants received nonspecific counseling in individual sessions (15-20 minutes) (eAppendix 2 in Supplement 2). 21, 30 Twelve weekly sessions of GPT and CM were followed by 10 monthly sessions over 52 weeks. 21, 30 The CM sessions were audio recorded and the GPT sessions were video recorded to assess treatment fidelity by 3 blinded, independent, expert raters.
21,30
Outcome Measures
Visits for assessing primary and secondary end points took place after randomization (baseline, or time 1 [T1]), after 12 weeks of intensive treatment (T2), during maintenance after 24 weeks (T3), at the end of treatment (week 52; T4), and at 2.5 years after T1 (follow-up; T5). The primary outcome was the change in the observer-rated CAARS ADHD Index from T1 to T2. Secondary outcome measures included other CAARS subscales, the ADHD-DC, the Beck Depression Inventory, 42, 43 and CGI subscales; we report results for these end points at T2 and T4. 
Statistical Analysis
Primary End Point Changes in the CAARS ADHD Index from T1 to T2 were analyzed by randomized treatment in the full analysis set. To model a stable postdropout response, missing postbaseline data were replaced using multiple imputation through last mean carried forward (LMCF) 44 in an analysis of covariance linear model, using time, treatments, center, and baseline measurements as fixed covariates (eAppendix 3 in Supplement 2). Adjusted means per treatment were calculated from this. For the primary treatment comparisons at T2, an additional interaction term (GPT × MPH; kept if significant at 10%) was pretested. The 2 primary comparisons were reported with confirmatory 97.5% confidence intervals (corrected for multiple testing of GPT vs CM and methylphenidate vs placebo) and descriptive 95% confidence intervals. These were statistically significant if P < .025 (P < .05 for other comparisons). If a primary treatment comparison was statistically significant, a confirmatory closed-test procedure sequentially compared GPT with methylphenidate vs CM with methylphenidate; GPT with methylphenidate vs GPT with placebo; CM with methylphenidate vs CM with placebo; and GPT with methylphenidate vs CM with placebo (descriptive reporting with nominal P values after the first nonsignificant result 21, 30 ).
Secondary End Points
Responses were defined as decreases in the observer rating variant of the CAARS ADHD Index of 30% or more. To calculate response rates, we analyzed only complete cases and used logistic regression. Other rating scales (other CAARS subscales, ADHD-DC, and Beck Depression Inventory) were evaluated using LMCF. Complete cases of CGI subscales (ordinal data) were analyzed in a proportional odds model.
Safety
Adverse events (AEs) were evaluated according to received treatment in safety set 1 (patients who attended ≥1 GPT or CM session) and safety set 2 (patients who received ≥1 dose of methylphenidate or placebo).
All analyses were prespecified and performed using SAS version 9.2 statistical software (SAS Institute, Inc).
Effect Sizes
Descriptive pre-post ESs were calculated using LMCF means and square roots of the residual variance, averaged over LMCF imputations as standard deviation.
Interim Analysis
An interim report on recruitment, compliance, and safety (no efficacy data) was presented to the independent data monitoring committee in April 2010, based on data up to T3 for the 231 patients randomized as of May 2009. The independent data monitoring committee recommended continuing the trial without modifications. Figure 1 
Results
Sample
Primary End Point at T2
The test for GPT × methylphenidate interaction was nonsignificant (P = .95). Therefore, a 2 × 2 approach (vs a 4-arm approach) was applied evaluating GPT vs CM and methylphenidate vs placebo.
Confirmatory 2-Arm Comparisons
The study detected no advantage for the decline in ADHD symptoms for GPT vs CM ( Table 2, Table 3 , and Figure 2 ). The ADHD Index scores improved from the all-group baseline mean of 20.6 to an adjusted mean of 17.6 at T2 for GPT (n = 209; ES = −0.55) and 16.5 for CM (n = 210; ES = −0.75) ( Table 2 and Figure 2 ). The difference between GPT and CM was nonsignificant (ADHD Index score difference for GPT vs CM, 1.1; 97.5% CI, −0.2 to 2.4; 95% CI, 0.0 to 2.2; P = .06). Symptoms decreased considerably more in patients assigned to methylphenidate (n = 210; adjusted mean ADHD Index score, 16.2; ES = −0.81) vs placebo (n = 209; adjusted mean ADHD Index score, 17.9; ES = −0.50) ( Table 2 and Figure 2 ). This difference proved significant (ADHD Index score difference for methylphenidate vs placebo, -1.7; 97.5% CI, −3.0 to −0.4; 95% CI, −2.8 to −0.6; P = .003).
Confirmatory 4-Arm Comparisons
Because the difference between methylphenidate and placebo proved significant, we applied sequential 4-arm analyses. In patients randomized to methylphenidate, GPT vs CM produced nonsignificant findings (ADHD Index score difference, 1.1; 95% CI, −0.4 to 2.7; P = .16). Thus, confirmatory statistical testing was terminated.
Further Descriptive Analyses
The following preplanned exploratory comparisons were conducted. Comparing methylphenidate with placebo in patients assigned to GPT showed that methylphenidate was superior to placebo (ADHD Index score difference, −1.7; 95% CI, −3.2 to −0.1; P = .04). This superiority was also evident in patients randomized to CM (ADHD Index score difference for methylphenidate vs placebo, −1.7; 95% CI, −3.3 to −0.2; P = .03). In contrast, comparing both interventions (GPT and methylphenidate) with the control treatments produced a nonsignificant benefit (ADHD Index score difference for GTP with methylphenidate vs CM with placebo,−0.6; 95% CI, −2.2 to 0.9; P = .43).
Secondary Outcomes
Long-term ADHD Index At T3 and T4, the treatment effects of GPT vs CM and methylphenidate vs placebo remained stable (Table 2 and Figure 2) . The slight disadvantage of GPT vs CM at T2 and T3 became a Response At T2, responses were highest in the CM with methylphenidate arm at 47.4%, compared with 32.5% in CM with placebo, 29.7% in GPT with methylphenidate, and 24.4% in GPT with placebo (GPT vs CM, P = .009; methylphenidate vs placebo, P = .05). At T4, response rates were similar in all 4 treatment arms, varying between 44.1% for GPT with placebo and 52.9% for CM with methylphenidate (GPT vs CM, P = .72; methylphenidate vs placebo, P = .52) ( Table 3 ).
Other Measures of ADHD Severity
For the self-ratings of the ADHD Index, GPT's nonsignificant disadvantage vs CM at T2 and T3 became a nonsignificant advantage at T4. Methylphenidate proved superior to placebo at all 3 measurement times ( Table 4) . The CAARS ratings and the ADHD-DC revealed comparable results in total and subscale scores, with no difference between GPT and CM ( Table 2 ; eTable 2 in Supplement 2).
Depression
Regarding depression, no significant differences were found between patients treated with GPT vs CM or methylphenidate vs placebo. Methylphenidate exhibited nonsignificantly better Beck Depression Inventory ratings at all 3 times. Moreover, GPT's nonsignificant disadvantage at T2 became a nonsignificant advantage at T4 (Table 4) .
CGI Scores
Comparison of CGI severity score between GPT and CM revealed no major differences ( Table 5) . Concerning CGI global change, GPT performed better than CM at all times; however, it was significant only at T4 (P = .047). Methylphenidate always performed better than placebo, but this was significant only at T3 (P = .008) ( Table 5 ). The end point CGI global assessment of effectiveness always favored GPT over CM and methylphenidate over placebo. This difference in GPT's favor was highly significant at T4 (P < .001) ( Table 5 ).
Safety
Frequencies of AEs and serious AEs are shown in eTable 3 in Supplement 2. No suicides occurred. Two patients receiving methylphenidate became pregnant, despite contraception. One terminated her pregnancy for psychosocial reasons; the other experienced no AEs during delivery or early development of the child. Changes in heart rate, blood pressure, and body weight from T1 to T4 are shown in eTable 4 in Supplement 2.
Discussion
The COMPAS is the first multimodal, multicenter randomized clinical trial to examine the efficacy of nonpharmacologi- 
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Treatment Efficacy for Adult Attention-Deficit/Hyperactivity Disorder pothesis, GPT could not be shown to be more effective than the CM control condition, except in CGI-related secondary outcomes. Methylphenidate was superior to placebo in nearly all outcome domains. All 4 treatment arms exhibited improvements in both symptoms and CGI ratings. This finding contrasts with previous findings in which preliminary evidence has shown the superiority of structured disorder-oriented GP T over unspec ific group control conditions. 23, 25, 26 However, our study used an individual CM control condition to simulate practice care in an optimal way. As a consequence, the investigated group program, although found effective in earlier preliminary studies, may not have been sufficiently effective to outperform the individual control condition. Another explanation may be that our control treatment-although performed adherent to the protocolwas not an attention placebo; instead, it included face-toface counseling activities, which potentially responded better to the individual needs of participants than the groups. We cannot extrapolate to specific psychotherapy methods beyond the one tested. While CM appeared superior to specific GPT after 3 months, long-term effects after 1 year favored GPT slightly. In particular, CGI global assessments of effectiveness of the interventions were significantly better for GPT at all measurement times. This is remarkable because this scale represents more general measures of well-being (eg, improved acceptance, selfesteem, coping skills), which were the focus of GPT.
Confirming preliminary evidence, 27 our trial clearly showed that combinations of GPT or CM with methylphenidate were superior to combinations with placebo.
Our study provides no evidence that methylphenidate reduces depressive symptoms. This contrasts with some preliminary evidence, 47 but it supports more recent research. 48, 49 Our results relate well to the large childhood Multimodal Treatment Study of Children With ADHD, 50 which also found A nonsignificant interaction term does not exclude the possibility that the effect of GPT may depend on MPH and vice versa. However, the 2-arm and 4-arm comparisons of GPT vs CM and GPT with methylphenidate vs CM with methylphenidate, as well as methylphenidate vs placebo and GPT with methylphenidate vs GPT with placebo, gave identical results, implying that our data do not suggest such dependencies.
Blinding was restricted to medication and to observer ratings of ADHD and CGI. We did not systematically assess whether blinding was effective in patients. However, because patients who received methylphenidate and those who received placebo both reported high numbers of AEs, with minimal effects to vital signs and weight, we believe the blinding was effective. As in other studies 51 and in line with the nature of the disorder, compliance was a challenge: more than one-third of the randomized patients dropped out. These missing data can be viewed as a study result 51 rather than as a shortcoming, since most dropouts occurred in the CM with placebo condition. Because the available data (eTable 5 in Supplement 2) and the imputed LMCF analyses of the full analysis set showed similar results, we conjecture that our findings were not confounded by dropouts. Our findings may not be generalizable to routine care settings in which comorbidities are not excluded and patients may have more psychosocial impairments or difficulties meeting the time and effort requirements for this trial.
Despite the significant superiority of methylphenidate vs placebo on most ADHD scales, the mean differences between methylphenidate vs placebo and GPT vs CM were relatively small. Our data could not show whether superior CGI ratings of GPT reflected otherwise hidden differences in patients' daily functioning.
Conclusions
The COMPAS trial sheds light on issues that, to our knowledge, have not yet been addressed. First, it almost doubles the observation period of the longest randomized study conducted globally so far. 52 Second, it systematically addresses the effect of medication on the outcome of psychotherapy. Previous studies were pilot studies, 27 not placebo controlled, [22] [23] [24] [25] [26] or included medication-treated patients with persistent ADHD symptoms. 16, 17, 25 Third, we compared a highly structured GPT with a less controlled CM condition, also an untested area. To our knowledge, COMPAS is the first trial to demonstrate long-term maintenance effects of ADHD treatments under controlled conditions. We demonstrate that psychological interventions result in better outcomes when combined with methylphenidate as compared with placebo. Our data do not suggest that highly structured group intervention outperforms individual CM, which is much easier to implement in practical care than specifically tailored and highly structured GPT.
